Enveloped viruses, vectors & immunotherapy
- Viral entry, assembly and interconnection with lipid metabolism
- Innovative technologies: viral particle engineering and novel humanized mouse models
- Translational developments: towards clinical and biotherapy applications
- Our studies on hepatitis C virus (HCV) assembly have led to the identification of p7 and NS2 HCV non-structural proteins as key determinants governing in concert the subcellular localization of HCV core and required for initiation of the early steps of virus assembly.
- We revealed a previously unsuspected mechanism of innate immunity in which exosomal export of viral RNA from infected cells serves as a host strategy to induce an innate response in cells whose innate signaling pathways are unopposed because they are not infected.
- We have invented lentiviral vectors pseudotyped with the glycoproteins from measles virus that allow for the first time robust transduction of resting T and B lymphocytes, which opens numerous applications in the field of cell and gene therapy.
- Our development of viral-like particle platforms, combining high bio-safety and strong immunogenicity features, has yielded proofs of concept for novel vaccine candidates against HCV and respiratory viruses such as avian influenza viruses and human metapneumovirus.
- European Research Council (ERC Advanced Grant “HEPCENT”)
- Agence Nationale pour la Recherche contre le SIDA et les Hépatites Virales (ANRS)
- Agence Nationale de la Recherche (ANR and ANR-JCJC “EXAMIN” to MD)
- European Community (FP7)
- Ligue Nationale Contre le Cancer (LNCC)
- AXA Foundation
- Fondation Finovi
- Fondation pour la Recherche Médicale (FRM)
- BPi France